Xolair: Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

(marketscreener.com) Builds on U.S. biosimilar portfolio of seven products with three commercial and four in pipeline 8th biosimilar expands portfolio into allergy treatments, a new therapeutic area https://www.marketscreener.com/quote/stock/AMNEAL-PHARMACEUTICALS-IN-43306881/news/Amneal-Expands-Biosimilars-Portfolio-to-Eight-Products-with-Addition-of-Omalizumab-Biosimilar-47276836/?utm_medium=RSS&utm_content=20240701